Precision Medicine And Aging Markets Will Fuel Oncology Despite Setbacks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
11 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$7.00
85.0% undervalued intrinsic discount16 Aug
US$1.05
1Y
-16.7%7D
27.9%